COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care.
Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and biotech companies optimize their research, development, and commercialization strategies.
COTA data includes over 2M+ patients across a variety of cancer diagnoses, treatment settings, and demographics and is regularly maintained and updated to ensure quality, accuracy, relevance, and linkability.
Get access to a massive database of longitudinal real-world outcomes datasets curated to specific cancer types, subpopulations, or broad population research.
Get expert clinical insights, study design support, and statistical analysis.
Explore our collection of clinical research, recent press, podcasts, and more.
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety…
Cancer affects everyone, including adolescents and young adults who are at increasing risk of developing certain types of disease. It’s a particularly challenging time of life to receive a cancer diagnosis. Many cancers in…
Cancer is a disease that respects no borders: it affects everyone around the world, no matter where they live. The universal nature of cancer makes it even more important for international partners to collaborate…
Partner with COTA for the highest-quality curated cancer patient datasets.
